@FiercePharma: ICYMI yesterday: Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say. Report | Follow @FiercePharma
@EricPFierce: ICYMI from FiercePharmaManufacturing: France's TxCell closes its plant at ANSM urging to avoid contamination. Article | Follow @EricPFierce
@CarlyHFierce: Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say. More | Follow @CarlyHFierce
> In a Phase III study, Merck's ($MRK) antivomiting drug for chemo patients, Emend, scored a statistically significant complete response rate among patients getting a moderately emetogenic (or vomit-inducing) chemotherapy. Story
> Brazilian authorities have fined Eli Lilly ($LLY) about $11 million for pursuing "sham" patent litigation. Report (sub. req.)
> India's Dr. Reddy's Laboratories ($RDY) is recalling two generic drugs from the U.S. market. More
> Menarini has won approval in Europe for an expanded indication for gout drug Adenuric. Release
> Pfizer Consumer Healthcare ($PFE) and Tris have inked a pact to market extended-release cough treatment Robitussin. More
> AMAG Pharmaceuticals ($AMAG) is buying the stem-cell storage company Cord Blood Registry for $700 million from private equity firm GTCR. More
> Bayer has submitted an application for its recombinant factor VIII hemophilia treatment in Japan. News
> AstraZeneca ($AZN) and the University of Cambridge have announced new joint PhD and clinical research scholarships. Release
Medical Device News
@FierceMedDev: UPDATED: Microchips Biotech partners with Teva on wireless drug delivery, announces new CEO, raises $18M in financing. FierceDrugDelivery story | Follow @FierceMedDev
@VarunSaxena2: FDA warns that transdermal patch for ADHD can lead to permanent skin discoloration. More from FierceDrugDelivery | Follow @VarunSaxena2
@EmilyWFierce: AdverseEvents flags TB reports, blood-disorder cases linked to RA drugs. FiercePharma report | Follow @EmilyWFierce
> Investors punish micro-cap EnteroMedics as it raises $35M to market recently approved obesity device. Report
> Startup gets CE mark for novel blood-draw tech after FDA clearance, Series A earlier this year. Story
> DOJ calls off investigation of Abiomed's Impella marketing. Article
Biotech News
@FierceBiotech: Biotech billionaire Soon-Shiong plots a second IPO for NantHealth. News | Follow @FierceBiotech
@JohnCFierce: Op-Ed: Is Celgene killing the traditional biotech partnering formula? More | Follow @JohnCFierce
@DamianFierce: $CELG is basically a microlending platform for oncology biotechs. More | Follow @DamianFierce
> Transgene is shedding 120 jobs to save cash and get its pipeline moving. Report
> Intercept files its 'breakthrough' liver drug for rare disease approval. Item
> Waksal's post-prison startup runs into more fraud allegations. Article
Drug Delivery News
> Cynapsus' sublingual Parkinson's med for levodopa nonresponders progresses to PhIII. Report
> Langer Lab company gets $5M in funding for drug-delivery device. Item
> OptiNose heralds late-stage clinical success for nasal anti-inflammatory. More
> Alnylam's hemophilia candidate reduces levels of anticoagulant in PhI study. Article
> FDA warns that transdermal patch for ADHD can lead to permanent skin discoloration. Story
Pharma Manufacturing News
> Capsugel completes $25M spray-dried expansion. Item
> India's Dr. Reddy's recalls 10 lots of two drugs that failed specifications. More
> Some Indian drugmakers see M&A preferable to investing in plant upgrades. Article
> Canada's Ropack buying Forest operations on Long Island. Story
> GSK doubles down on Singapore continuous processing plant. Report
Pharma Asia News
> Blurred lines in Japan's vision for healthcare in next two decades. Report
> Out with the old, reimburse the new: Merck's Frazier wades into Australia drug debate. More
> Troubled India's Wockhardt sees third U.S. drug recall in as many months. Report
> No artful tax dodging here, drug firms tell Australia transfer-price inquiry. Story
> Taiwan's PharmaEngine racks up good news on MM-398. Article
And Finally... Only about one in 8 pre-diabetic people know they have a problem, a new study shows. Report